SiBone (NASDAQ:SIBN) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. lowered its holdings in shares of SiBone (NASDAQ:SIBN - Free Report) by 12.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,187,398 shares of the company's stock after selling 453,047 shares during the quarter. Brown Advisory Inc. owned 7.51% of SiBone worth $44,719,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of SIBN. Proficio Capital Partners LLC purchased a new position in SiBone during the 4th quarter valued at $155,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of SiBone by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 321,263 shares of the company's stock worth $4,504,000 after buying an additional 6,171 shares during the period. Raymond James Financial Inc. bought a new position in SiBone during the 4th quarter worth about $1,233,000. AlphaQuest LLC increased its position in SiBone by 13,950.6% during the 4th quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock valued at $164,000 after purchasing an additional 11,579 shares during the period. Finally, First Eagle Investment Management LLC purchased a new position in SiBone during the 4th quarter valued at about $2,600,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

SiBone Price Performance

SIBN stock traded down $1.58 during mid-day trading on Friday, reaching $17.20. 382,421 shares of the company's stock were exchanged, compared to its average volume of 393,206. The company has a market cap of $733.06 million, a price-to-earnings ratio of -26.88 and a beta of 0.93. The stock's 50 day moving average is $18.23 and its 200 day moving average is $16.34. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.53 and a quick ratio of 7.26. SiBone has a 12-month low of $11.70 and a 12-month high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. The business had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. On average, research analysts expect that SiBone will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

SIBN has been the topic of a number of research reports. Truist Financial raised their target price on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th.

Insider Transactions at SiBone

In related news, Director Jeffrey W. Dunn sold 3,377 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $19.05, for a total value of $64,331.85. Following the completion of the sale, the director owned 17,354 shares of the company's stock, valued at approximately $330,593.70. This trade represents a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 5,005 shares of the firm's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $18.34, for a total value of $91,791.70. Following the sale, the chief financial officer directly owned 217,078 shares of the company's stock, valued at approximately $3,981,210.52. This trade represents a 2.25% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,702 shares of company stock valued at $1,866,404. 4.00% of the stock is currently owned by company insiders.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.